There were 732 press releases posted in the last 24 hours and 166,238 in the last 365 days.

CRISPR Therapeutics to Host Conference Call and Webcast to Provide an Update on the CRISPR/Cas9 U.S. Patent Interference Proceedings and Corresponding U.K. Patents

BASEL, Switzerland and CAMBRIDGE, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that management will host a conference call and live audio webcast on Thursday, February 16, 2017 at 11:00 a.m. ET to provide an update on the CRISPR/Cas9 U.S. Patent Interference Proceedings as well as an update on the corresponding U.K. patents.   

To access the conference call, please dial +1 (844) 358-8762 (domestic) or +1 (703) 736-7374 (international) and reference the conference ID number 74645402.  To join the live webcast, please visit the “Investors & Media” section of the CRISPR Therapeutics website at

A webcast replay will be available on the CRISPR Therapeutics website beginning approximately two hours after the event and will be archived for 30 days.

CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the Company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit

Jennifer Paganelli
W2O Group for CRISPR

Chris Brinzey
Westwicke Partners for CRISPR

/EIN News/ -- Primary Logo

Distribution channels: Conferences & Trade Fairs, Technology